Trial Profile

A Phase 1, First-in-human, Randomized, Double Blind, Placebo Controlled, Safety, Tolerability and Pharmacokinetic Study of ABY 039 in Healthy Subjects

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 19 Jun 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tifalibep (Primary) ; Tifalibep (Primary)
Indications Autoimmune disorders
Focus Adverse reactions; First in man
Sponsors Affibody

Most Recent Events

16 Jun 2020 Status changed from completed to discontinued.
15 Jun 2020 According to an Affibody media release, ABY-039 program is terminated due to tolerability observations that would limit the target product profile of subcutaneous high dose once monthly maintentance injections.The termination will become effective June 18, 2020.
15 Jun 2020 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com